Q-omics provides the consensus-scored KNCN profile across patient tissues and cancer cell-line models. KNCN expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KNCN is differentially expressed in 6, with the highest sampling consensus in LUSC. Additionally, KNCN RNA expression shows 7,699 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LUSC, and TGCT as cancer lineages where KNCN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KNCN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KNCN survival associations across molecular data types. KNCN RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KNCN RNA expression–survival associations across cancer types. High KNCN expression shows unfavorable associations in KIRC, ACC, UVM, STAD and LIHC, but favorable associations in SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for KNCN RNA expression.
This table summarizes KNCN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for KNCN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KNCN shows lower tumor expression in LUSC, LUAD, READ and KIRC and higher tumor expression in BRCA and PRAD. The LUSC box plot shows higher KNCN RNA expression in normal versus tumor tissue (log2 FC = −0.064, t-test p < 0.001).
This table shows molecular features associated with KNCN in patient tissues and cancer cell lines. In patient samples, KNCN shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KNCN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
